Shezad Malik Law Firm Dr Shezad Malik Law Firm has offices based in Fort Worth and Dallas and represents people who have suffered catastrophic and serious personal injuries including wrongful death, caused by the negligence or recklessness of others. We specialize in Personal Injury trial litigation and focus our energy and efforts on those we represent.

Articles Tagged with Onglyza

Onglyza Heart Failure Injuries Lawsuits Centralized. Recently, the U.S. Judicial Panel on Multidistrict Litigation (JPML) has ordered that all filed federal Onglyza heart failure injuries lawsuits be consolidated and centralized as part of multidistrict litigation or MDL.

Onglyza Heart Failure Injuries

Onglyza Heart Failure Injuries. Onglyza and Kombiglyze linked to heart failure according to the FDA Warning

Type 2 diabetic patients who used Onglyza and developed heart problems allegedly caused by the diabetes drug will be consolidated in the U.S. District Court Eastern District of Kentucky, before U.S. District Judge Karen Caldwell.

Onglyza Heart Failure. Wrendell Chester, from Texas, recently filed a personal injury and product liability lawsuit, against Bristol-Myers Squibb and AstraZeneca, the manufacturers of the drug.

Onglyza Heart Failure Attorney

Onglyza and Kombiglyze linked to heart failure according to the FDA Warning

Chester claims that the companies failed to adequately warn patients and doctors about the risk of heart failure from side effects of Onglyza and failed to conduct proper research and testing.

In the federal court system, a Multidistrict Litigation (MDL) has been established to centralize Byetta, Januvia, Janumet and Victoza pancreatic cancer lawsuits filed in U.S. District Courts by the users of these diabetic drugs.

There are currently at least 262 cases consolidated as part of an MDL, before U.S. District Judge Battaglia in the Southern District of California. Next discovery and pretrial proceedings will proceed, and bellwether trials will be scheduled, probably some time in 2015.

The National Institutes of Health held a workshop, addressing the risks associated with the newer diabetic drugs. These medications, known as Incretic Mimetics are coming under fire for alleged increased risk of pancreatic cancer.

Merck & Co., Novo Nordisk A/S and others, the manufacturers of these drugs may be asked to collect more data on a potential cancer link even as they try to reassure U.S. regulators this week of the drugs’ safety.

The Food and Drug Administration said it is considering setting up a study, either through the agency or the companies, that looks deeper into whether medicines for Type 2 diabetes, including Merck’s Januvia and Bristol Myers-Squibb Co.’s Byetta, cause pancreatic cell growth that could turn cancerous.

Contact Information